UBS Group’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,387
| Closed | -$2.71K | – | 10456 |
|
|
2023
Q4 | $2.71K | Buy |
+1,387
| New | +$2.79K | ﹤0.01% | 8064 |
|
|
2023
Q3 | – | Sell |
-24
| Closed | -$71 | – | 10375 |
|
|
2023
Q2 | $71 | Buy |
+24
| New | +$128 | ﹤0.01% | 8561 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 9521 |
|
|
2022
Q4 | – | Sell |
-1,103
| Closed | -$12.8K | – | 10671 |
|
|
2022
Q3 | $16K | Buy |
1,103
+593
| +116% | +$14.6K | ﹤0.01% | 7753 |
|
|
2022
Q2 | $30K | Buy |
510
+482
| +1,721% | +$69.9K | ﹤0.01% | 6410 |
|
|
2022
Q1 | $12K | Buy |
28
+26
| +1,300% | +$16.6K | ﹤0.01% | 8245 |
|
|
2021
Q4 | $2K | Buy |
+2
| New | +$2.82K | ﹤0.01% | 9892 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 10401 |
|
|
2021
Q2 | – | Sell |
-7
| Closed | -$23.1K | – | 9250 |
|
|
2021
Q1 | $28K | Hold |
7
| – | – | ﹤0.01% | 7075 |
|
|
2020
Q4 | $42K | Buy |
+7
| New | +$41.2K | ﹤0.01% | 6346 |
|
|
2020
Q3 | – | Sell |
-11
| Closed | -$63K | – | 7593 |
|
|
2020
Q2 | $61K | Buy |
+11
| New | +$57.2K | ﹤0.01% | 5707 |
|
|
2020
Q1 | – | Sell |
-2
| Closed | -$12K | – | 8576 |
|
|
2019
Q4 | $12K | Buy |
+2
| New | +$6.99K | ﹤0.01% | 7204 |
|
|
2019
Q3 | – | Sell |
-3
| Closed | -$9K | – | 8373 |
|
|
2019
Q2 | $9K | Hold |
3
| – | – | ﹤0.01% | 7153 |
|
|
2019
Q1 | $9K | Sell |
3
-3
| -50% | -$6.36K | ﹤0.01% | 6902 |
|
|
2018
Q4 | $7K | Buy |
+6
| New | +$9.19K | ﹤0.01% | 7440 |
|
|
2018
Q3 | – | Sell |
-2
| Closed | -$1K | – | 8376 |
|
|
2018
Q2 | $1K | Hold |
2
| – | – | ﹤0.01% | 7863 |
|
|
2018
Q1 | $10K | Buy |
+2
| New | +$13.2K | ﹤0.01% | 6893 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$4K | – | 8188 |
|
|
2017
Q3 | $4K | Hold |
1
| – | – | ﹤0.01% | 7337 |
|
|
2017
Q2 | $8K | Buy |
+1
| New | +$6.92K | ﹤0.01% | 6938 |
|
|
2017
Q1 | – | Sell |
-2
| Closed | -$10.1K | – | 7492 |
|
|
2016
Q4 | $17K | Buy |
+2
| New | +$28K | ﹤0.01% | 6623 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7146 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7358 |
|
|
2016
Q1 | – | Sell |
-2
| Closed | -$25.8K | – | 6950 |
|
|
2015
Q4 | $39K | Buy |
2
+1
| +100% | +$15.8K | ﹤0.01% | 6067 |
|
|
2015
Q3 | $19K | Hold |
1
| – | – | ﹤0.01% | 6760 |
|
|
2015
Q2 | $19K | Hold |
1
| – | – | ﹤0.01% | 6929 |
|
|
2015
Q1 | $16K | Buy |
+1
| New | +$17.5K | ﹤0.01% | 7233 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 9296 |
|
Other funds holding AGRX
UBS Group's AGRX Position: Q1 2024 in Review
UBS Group sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 1,387 shares — an estimated $2.71K sold.
UBS Group first reported a position in AGRX in Q1 2015 and held it in 22 quarters. The position peaked at $61K in Q2 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- UBS Group reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 1,387 Agile Therapeutics shares in Q1 2024, an estimated $2.71K.
- UBS Group first reported a position in Agile Therapeutics in Q1 2015 and held it in 22 quarters.
- UBS Group's Agile Therapeutics position peaked at $61K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.